ISM3830

Insilico nominates ISM3830, a potentially best-in-class, orally available and highly selective CBLB inhibitor with an AI‑empowered novel scaffold, as a preclinical candidate (PCC) for advanced tumor immunotherapy. The development process was empowered by Insilico’s Chemistry42 generative design suite, with a special focus on ADMET Profiling the predictor application, securing distinctive advantages including promising ADME/PK profile and safety profile. In preclinical studies, ISM3830 showed robust in vivo anti‑tumor activity in multiple murine models, induction of long‑term tumor immunity, and combination potential with immune checkpoint inhibitors, chemotherapies and targeted agents. IND‑enabling studies are being initiated to support first‑in‑human evaluation in patients with advanced solid tumors. Empowered by Insilico’s proprietary generative AI platform, the drug candidate overcomes the current bottlenecks of CBLB inhibition therapies in metabolism and absorption. Preclinical safety screening demonstrated low risk of hypotension, gastrointestinal toxicity, and off-target toxicity, as well as excellent selectivity and improved safety margin in DRF study. Promising druggability and excellent ADME/PK profile both in vitro and in vivo, measured by lower in vivo clearance, and higher oral bioavailability across preclinical species.